These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1436 related articles for article (PubMed ID: 28500517)
1. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Adhyaru BB; Jacobson TA Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517 [TBL] [Abstract][Full Text] [Related]
2. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926 [TBL] [Abstract][Full Text] [Related]
3. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond. Waite LH; Phan YL; Spinler SA J Am Pharm Assoc (2003); 2016; 56(3):284-92. PubMed ID: 27156942 [TBL] [Abstract][Full Text] [Related]
4. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
5. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
6. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708 [TBL] [Abstract][Full Text] [Related]
7. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491 [TBL] [Abstract][Full Text] [Related]
8. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517 [TBL] [Abstract][Full Text] [Related]
9. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394 [TBL] [Abstract][Full Text] [Related]
10. Statins and PCSK9 inhibitors: A new lipid-lowering therapy. Gallego-Colon E; Daum A; Yosefy C Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598 [TBL] [Abstract][Full Text] [Related]
11. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775 [TBL] [Abstract][Full Text] [Related]
12. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. O'Keefe JH; DiNicolantonio JJ; Lavie CJ Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940 [TBL] [Abstract][Full Text] [Related]
13. 2017 Taiwan lipid guidelines for high risk patients. Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI; J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176 [TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543 [TBL] [Abstract][Full Text] [Related]
15. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Wójcik C Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791 [TBL] [Abstract][Full Text] [Related]
16. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Lee S; Cannon CP Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475 [TBL] [Abstract][Full Text] [Related]
17. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
18. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356 [TBL] [Abstract][Full Text] [Related]
19. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086 [TBL] [Abstract][Full Text] [Related]
20. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease. Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]